Advertisement

Arachidonate—Phospholipid Remodeling and Cell Proliferation

  • Floyd H. Chilton
  • Marc E. Surette
  • James D. Winkler
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 416)

Abstract

It has been recognized since the mid-1980’s that arachidonic acid is taken up and remodeled between as many as 20 different glycerolipid molecular species in most cell types [1]. However, it has been difficult to understand why it is necessary for mammalian cells to maintain so many different arachidonate-containing glycerolipids and the ramifications of remodeling arachidonate between different glycerolipid molecular species. It is known that arachidonate-phospholipid remodeling occurs at a relative“slow” rate in most resting cells but this rate can be accelerated many fold during priming or stimulation of cells [2, 3]. Recently, we have begun to utilize newly-discovered inhibitors of the enzyme, CoA-independent transacylase (CoA-IT), which is thought to remodel arachidonate into the phospholipid subclass 1-alkyl-2-arachidonoyl-GPC and ethanolamine-containing phospholipids. Using these inhibitors of remodeling, it has been discovered that rapid remodeling of arachidonate is probably necessary to support continued arachidonic acid release and PAF generation which is initiated by phospholipase A2.

Keywords

Arachidonic Acid Arachidonic Acid Release Normal Bone Marrow Cell Bowman Gray School Exogenous Arachidonic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chilton, F.H. and Murphy, R.C. (1986) J. Biol. Chem. 261, 7771PubMedGoogle Scholar
  2. 2.
    Fonteh, A.N. and Chilton, F.H. (1992) J. Immunol. 148, 1784PubMedGoogle Scholar
  3. 3.
    Winkler, J.D., Sung, C.M., Huang, L. and Chilton, F.H. (1994) Biochim Biophys Acta 1215, 133Google Scholar
  4. 4.
    Berdel, W.E., Bausert, W.R., Fink, U., Rastetter, J. and Munder, P.G. (1981) Anticancer Res 1 (6), 345PubMedGoogle Scholar
  5. 5.
    Modolell, M., Andreesen, R., Pahlke, W., Brugger, U. and Munder, P.G. (1979) Cancer Res 39, 4681PubMedGoogle Scholar
  6. 6.
    Hoffman, D.R., Hajdu, J. and Snyder, F. (1984) Blood 63, 545PubMedGoogle Scholar
  7. 7.
    Winkler, J.D., Sung, C.M., Bennett, C.F. and Chilton, F.H. (1991) Biochim Biophys Acta 1081, 339Google Scholar
  8. 8.
    Diomede, L., Colotta, F., Piovani, B., Re, F., Modest, E.J. and Salmona, M. (1993) Int J Cancer 53, 124PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Floyd H. Chilton
    • 1
    • 2
  • Marc E. Surette
    • 1
  • James D. Winkler
    • 3
  1. 1.Department of Medicine (Pulmonary and Critical Care Medicine)Bowman Gray School of Medicine of Wake Forest UniversityWinston-SalemUSA
  2. 2.Department of BiochemistryBowman Gray School of Medicine of Wake Forest UniversityWinston-SalemUSA
  3. 3.Division of PharmacologySmithkline Beecham PharmaceuticalsKing of PrussiaUSA

Personalised recommendations